Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8664631 | 1.00 | AOC2 (0.36) | AOC2ALDH1A1PTGS2CA2CA12 | |
| SCHEMBL9010034 | 0.94 | PTGS2 (0.38) | ALDH1A1PTGS2S1PR3PTGS1SNCA | |
| SCHEMBL872698 | 0.92 | ALDH1A1 (0.38) | AOC2ALDH1A1CA2CA12CA1 | |
| SCHEMBL29006523 | 0.88 | PTGS2 (0.45) | PTGS2S1PR3PTGS1SNCA | |
| SCHEMBL10317771 | 0.87 | S1PR3 (0.37) | ALDH1A1HTTS1PR3SNCAPTGER4 | |
| SCHEMBL900004 | 0.87 | GAA (0.38) | ALDH1A1PTGS2HTTS1PR3PTGS1 | |
| SCHEMBL1607370 | 0.86 | S1PR3 (0.43) | ALDH1A1PTGS2CA2CA12CA1 | |
| SCHEMBL8750988 | 0.84 | S1PR3 (0.41) | ALDH1A1HTTS1PR3PTGER4 | |
| SCHEMBL10596213 | 0.82 | ALDH1A1 (0.41) | ALDH1A1CA2CA12CA1HTT | |
| SCHEMBL14915169 | 0.81 | S1PR3 (0.41) | AOC2ALDH1A1HTTS1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094516-B2 | Benzobisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2006-08-22 | — | — | US | disclosed |
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1245571-A1 | BENZBISAZOLE COMPOUND AND OPTICAL RECORDING MEDIUM CONTAINING THE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2002-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | DAO, CACNA1I, KCNB2 | AOC2 71/4885ALDH1A1 838/4885PTGS2 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.